Moberg Pharma AB's Kjell Rensfeldt will retire as vice president of research and development and chief medical officer.
The Sweden-based pharmaceutical company said Rensfeldt will continue to serve as a senior adviser on a part-time basis following his retirement "during the fall," according to an Aug. 13 release.
Shaw Sorooshian will replace Rensfeldt as Moberg Pharma's vice president and chief medical officer. Sorooshian is joining the company from Swedish Orphan Biovitrum AB, a global rare disease company, where he served as senior director of global medical affairs. Prior to Sobi, he held senior roles at Shire PLC, H. Lundbeck A/S and Organon Laboratories Ltd.